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ABSTRACT 
The paralysis tick of Australia, Ixodes holocyclus, causes a severe toxicosis in 
domestic animals such as dogs and cats, livestock, and in some cases humans. It is 
characterised by a rapidly ascending flaccid paralysis. The causative agent of the 
toxicosis is a neurotoxin produced in the tick salivary glands. The current treatment 
for tick paralysis is in the form of a polyclonal dog antiserum. This antiserum 
treatment is expensive and effective only in the early stages of paralysis. 
This thesis describes the isolation of the cDNA sequence for the neurotoxin HT-1 
of I. holocyclus. In addition it describes the successful expression of the mature HT-
1 toxin as a fusion protein in a bacterial host system and attempts at expression of 
this recombinant protein in the absence of a fusion partner in a baculovirus system. 
The anti genic and protective properties of the HT -1 fusion protein raised in mice and 
dogs is also discussed. 
The complete cDNA sequence of the HT-1 neurotoxin was determined using the 
technique of RACE-PCR. The derived protein sequence of the mature toxin has a 
calculated molecular weight of 5.9 kDa and contains 8 cysteine residues, suggesting 
that it can form four disulphide bonds. The HT-1 protein sequence shares 
similarities with other arachnid neurotoxins. Examples of these similarities are its 
small size, number and arrangement of cysteine residues and in the length and 
composition of its signal sequence. 
A recombinant form of the HT-1 toxin was produced as a fusion protein in an E.coli 
host system. The fusion protein was shown to be immunogenic by Western blot and 
ELISA analysis. The antibodies produced against the recombinant fusion protein 
show partial protection against native toxin in mouse assays. Dogs immunised with 
the recombinant fusion protein produced specific antibodies to HT-1 as 
demonstrated in ELISA assay. However, these antibodies were not protective when 
the dogs were challenged with numerous live ticks. 
The results obtained have contributed a novel tick neurotoxin sequence which as a 
fusion protein produces antibodies that exhibit partial protection in mice against 
native toxin challenge. These results provide some optimism and basic 
understanding of what is required for the future development of a recombinant 
vaccine against paralysis caused by the tick I. holocyclus. 
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